Programmed death 1 (PD-1) axis inhibitor monotherapies, including nivolumab, are currently standard salvage therapy for patients with immunotherapy-naive advanced non–small cell lung cancer (NSCLC) that has progressed on platinum-doublet chemotherapy.1,2,3,4 The PD-1 axis inhibitors pembrolizumab and atezolizumab have additionally been approved for use as first-line monotherapy in patients with advanced NSCLC expressing programmed death-ligand 1 (PD-L1) or in combination with chemotherapy regardless of tumor PD-L1 expression.5,6,7,8,9,10,11. The gene discussed is CD274; the disease is neoplasm.